Research
Premium Reports
Decision-grade industry intelligence for leadership teams and investors. Built from operator interviews and regulatory analysis that does not appear in analyst reports.
Read by CEOs, COOs, VPs of Quality, MSAT, and BD, plus institutional investors, across radiopharma, ADC, and CDMO companies in the UK, US, EU, and Asia.
The ADC Supply Squeeze
Announced capacity is not staffed capacity. The supply-side read of who can actually make an ADC, where the chain chokes, and the talent gap nobody has hired for.
From $1,495
Read moreThe State of Radiopharmaceuticals 2026
The definitive operating-reality assessment of the global radiopharmaceutical sector.
From $1,495
Read moreThe Isotope Production Map 2026
The definitive map of the global radiopharmaceutical isotope supply chain.
From $1,495
Read moreCDMO Weaponised Capacity 2026
The definitive guide to CDMO strategy, selection, and valuation in the post-BIOSECURE era.
From $1,495
Read moreThe State of ADCs 2026
ADCs are being priced as biology businesses. The risk sits in chemistry, manufacturing, and capital structure.
From $1,495
Read moreBespoke Work
Custom Intelligence
When the question you need answered is not in any published report. Recent commissions have covered radiopharma CDMO capacity mapping, CGT technology acquisition diligence, and BD leadership compensation benchmarks across US and EU CROs, CDMOs, and complex modality sponsors. Same operator network, same research methods, scoped to your question.